 14 PM / in 6 minutes BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S. Reuters Staff 1 Min Read 
Jan 24 (Reuters) - Spark Therapeutics Inc: 
* SPARK THERAPEUTICS ENTERS INTO A LICENSING AND SUPPLY AGREEMENT FOR INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE THE U.S. 
* SPARK THERAPEUTICS INC - SPARK THERAPEUTICS TO RECEIVE $105 MILLION AS AN UPFRONT FEE UNDER AGREEMENT 
* SPARK THERAPEUTICS INC - CO ALSO ENTERED INTO A SEPARATE AGREEMENT TO MANUFACTURE AND SUPPLY INVESTIGATIONAL VORETIGENE NEPARVOVEC TO NOVARTIS 
* SPARK THERAPEUTICS INC - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $65 MILLION IN CASH MILESTONE PAYMENTS 
* SPARK THERAPEUTICS INC - NO OTHER PROGRAMS IN SPARK THERAPEUTICSâ€™ PIPELINE ARE PART OF THIS AGREEMENT 
* SPARK THERAPEUTICS INC - CO IS ALSO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE U.S Source text for Eikon: Further company coverage: